Skip to main content
. 2015 Mar 26;125(19):3024–3031. doi: 10.1182/blood-2015-01-623991

Figure 2.

Figure 2

Risk-stratified outcomes of NMA haplo BMT based on refined DRI group. (A) Progression-free survival. (B) Overall survival. (C) Cumulative incidence of relapse. (D) Cumulative incidence of nonrelapse mortality. Point estimates are provided in Table 2. Int., intermediate; V, very.